Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215962 · ClinicalTrials.gov registry record
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
A clinical trial of Non-small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07215962 is a study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 300 participants, roughly in line with the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07215962, a study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab + ipilimumab
- BIOLOGICAL Nivolumab + ipilimumab + platinum-based chemotherapy
- BIOLOGICAL Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
- BIOLOGICAL Other dual-immuno-oncology therapy with chemotherapy
Study Locations (1)
Florida
- Florida Cancer Specialists & Research Institute - Fleming Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2026-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215962
The ClinicalTrials.gov registry entry for NCT07215962 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab + ipilimumab is the first listed.
NCT07215962 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07215962 about?
NCT07215962 is a clinical study titled "Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%". The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy
What is the current status of trial NCT07215962?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2024-11-22. Estimated completion is 2026-03-01.
What conditions does trial NCT07215962 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07215962?
The interventions under investigation include: Nivolumab + ipilimumab (BIOLOGICAL), Nivolumab + ipilimumab + platinum-based chemotherapy (BIOLOGICAL), Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy (BIOLOGICAL), Other dual-immuno-oncology therapy with chemotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT07215962?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215962 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.